LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback